Search results
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
CNBC· 7 hours agoEli Lilly & Co.'s shares climbed in early US trading after its experimental drug for Alzheimer's...
FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations
WUSF 89.7· 8 hours agoAll 11 committee members also recommended that doctors and patients have the option of halting...
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
CNN via Yahoo News· 1 hour agoOn Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early ...
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
Yahoo Finance· 6 hours agoThe trial studied the drug's ability to address beta-amyloid plaque buildup associated with dementia...
FDA panel backs Eli Lilly’s Alzheimer’s drug
The Hill· 4 hours agoA federal advisory panel on Monday voted in favor of recommending Eli Lilly’s new drug that is under consideration for its potential to slow the...
Lilly's Alzheimer's drug faces delayed reckoning
Axios· 15 hours agoWhy it matters: Their conclusions could influence how the FDA treats future drugs that target proteins in the brain known as amyloid plaques that are...
Lilly Alzheimer's drug gets unanimous backing from FDA advisory panel
Reuters via AOL· 15 hours ago(Reuters) -Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously...
US FDA advisers to review Eli Lilly Alzheimer's drug
Reuters· 15 hours agoBoth drugs are designed to remove toxic beta amyloid plaques from the brains of people with early Alzheimer's disease. The antibody treatments, which...
Donanemab for Alzheimer's Gets Thumbs Up From FDA Panel
Medscape· 22 hours agoAn 11-member advisory panel to the US Food and Drug Administration (FDA) has unanimously concluded...
Unanimous FDA panel backs Lilly Alzheimer's drug
Axios· 3 hours agoA unanimous panel of federal drug advisers on Monday concluded that Eli Lilly's experimental Alzheimer's drug donanemab benefits patients with early...